EQT Life Sciences leads $20 Million Financing Round in FundamentalVR



FundamentalVR receives Series B growth investments to disrupt the medical simulation market – expected to be worth $4.2 billion by 2025.

 

Amsterdam, the Netherlands, August 11, 2022 – FundamentalVR has raised $20 million to significantly accelerate medical skill-transfer and to increase surgical proficiency through its world-leading medical simulation platform, Fundamental Surgery.

 

The transaction was led by EQT Life Sciences, investing from the LSP Health Economics Fund 2, and joined by prior investors Downing Ventures. The new investments follows a Series A round from October 2019, and brings the company’s total funding to over $30 million.

 

FundamentalVR is the world’s first scalable medical simulation platform to combine virtual reality and haptics through data, artificial intelligence, and multimodal learning. FundamentalVR’s patented HapticVR™ technology mimics the physical touch of surgical actions which allows users to experience the sights, sounds, and physical sensations of real-life surgery. Scalable and hardware agnostic, the platform immerses users in a controlled training environment that lowers the surgical risk to patients.

 

Deployed in over 30 countries, FundamentalVR’s high-fidelity simulations helps life sciences, pharmaceutical and med-device companies deploy medical innovations in disciplines from ophthalmology, to robotics, gene therapy, and more. The growth investment will enable further development of HapticVR™, the machine learning data insights product, and geographic expansion throughout the US. FundamentalVR’s multiuser platform enables medical institutions, hospitals, and surgical educators, to scale professionally accredited surgical training throughout their organisations. Partnerships with hospital groups, including flagship clients and investors Mayo Clinic and Sana Kliniken, will drive further growth.

 

“Our platform can conduct a walkthrough of a procedure through to a full operation, facilitating surgical skills transfer – which is why we have been enthusiastically embraced throughout the medical industry, from med-device manufacturers to pharmaceuticals” says co-Founder and Chief Executive Richard Vincent. “Our immersive environments transform surgical skills acquisition in a scalable, low-cost, multiuser way. We are excited to scale our vision of creating a medical education environment unhindered by borders."

 

“With increasingly complex surgical procedures, it is important to provide medical professionals with new methods for surgical skills transfer and continued training and education, whilst managing both the cost and time burden associated with these activities” said Drew Burdon, Partner at EQT Life Sciences. HapticVR™, is a differentiated approach which has already been adopted by a number of high-quality customers, in a short period of time, demonstrating the value that this system can add today”.

 

As part of the transaction, Drew Burdon will join the Board of Directors.

 

About FundamentalVR
FundamentalVR delivers immersive multi-user simulations ‘Blended VR’ underpinned with HapticVR™ interactions that enable medical devices and procedures to drive consistency and compliance across their training programs provided on the multimodal Fundamental Surgery platform. The platform allows for full rehearsal of medical and surgical procedures, providing deep data insight into competency and skills development, accelerating safe adoption across the board, and is the only platform accredited by leading global education institutions. The unlimited multi-user capabilities and mixed modalities all work individually or together for each business case, accelerating the time in which products and procedures can be brought to market and improve patient outcomes.
 
 
About EQT Life Sciences
EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients.
 
The team combines deep sector knowledge, analytical skills, and investment experience to provide the added value that inventors seek. EQT Life Sciences’ broad life sciences and healthcare network is highly complementary to EQT’s global healthcare sector franchise and makes EQT an even better and more innovative healthcare investor.
 
 
More info: www.eqtgroup.com/lifesciences
Follow EQT on LinkedInTwitterYouTube and Instagram

 

« back to overview
Follow us

EQT Life Sciences leads $20 Million Financing Round in FundamentalVR



FundamentalVR receives Series B growth investments to disrupt the medical simulation market – expected to be worth $4.2 billion by 2025.

 

Amsterdam, the Netherlands, August 11, 2022 – FundamentalVR has raised $20 million to significantly accelerate medical skill-transfer and to increase surgical proficiency through its world-leading medical simulation platform, Fundamental Surgery.

 

The transaction was led by EQT Life Sciences, investing from the LSP Health Economics Fund 2, and joined by prior investors Downing Ventures. The new investments follows a Series A round from October 2019, and brings the company’s total funding to over $30 million.

 

FundamentalVR is the world’s first scalable medical simulation platform to combine virtual reality and haptics through data, artificial intelligence, and multimodal learning. FundamentalVR’s patented HapticVR™ technology mimics the physical touch of surgical actions which allows users to experience the sights, sounds, and physical sensations of real-life surgery. Scalable and hardware agnostic, the platform immerses users in a controlled training environment that lowers the surgical risk to patients.

 

Deployed in over 30 countries, FundamentalVR’s high-fidelity simulations helps life sciences, pharmaceutical and med-device companies deploy medical innovations in disciplines from ophthalmology, to robotics, gene therapy, and more. The growth investment will enable further development of HapticVR™, the machine learning data insights product, and geographic expansion throughout the US. FundamentalVR’s multiuser platform enables medical institutions, hospitals, and surgical educators, to scale professionally accredited surgical training throughout their organisations. Partnerships with hospital groups, including flagship clients and investors Mayo Clinic and Sana Kliniken, will drive further growth.

 

“Our platform can conduct a walkthrough of a procedure through to a full operation, facilitating surgical skills transfer – which is why we have been enthusiastically embraced throughout the medical industry, from med-device manufacturers to pharmaceuticals” says co-Founder and Chief Executive Richard Vincent. “Our immersive environments transform surgical skills acquisition in a scalable, low-cost, multiuser way. We are excited to scale our vision of creating a medical education environment unhindered by borders."

 

“With increasingly complex surgical procedures, it is important to provide medical professionals with new methods for surgical skills transfer and continued training and education, whilst managing both the cost and time burden associated with these activities” said Drew Burdon, Partner at EQT Life Sciences. HapticVR™, is a differentiated approach which has already been adopted by a number of high-quality customers, in a short period of time, demonstrating the value that this system can add today”.

 

As part of the transaction, Drew Burdon will join the Board of Directors.

 

About FundamentalVR
FundamentalVR delivers immersive multi-user simulations ‘Blended VR’ underpinned with HapticVR™ interactions that enable medical devices and procedures to drive consistency and compliance across their training programs provided on the multimodal Fundamental Surgery platform. The platform allows for full rehearsal of medical and surgical procedures, providing deep data insight into competency and skills development, accelerating safe adoption across the board, and is the only platform accredited by leading global education institutions. The unlimited multi-user capabilities and mixed modalities all work individually or together for each business case, accelerating the time in which products and procedures can be brought to market and improve patient outcomes.
 
 
About EQT Life Sciences
EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients.
 
The team combines deep sector knowledge, analytical skills, and investment experience to provide the added value that inventors seek. EQT Life Sciences’ broad life sciences and healthcare network is highly complementary to EQT’s global healthcare sector franchise and makes EQT an even better and more innovative healthcare investor.
 
 
More info: www.eqtgroup.com/lifesciences
Follow EQT on LinkedInTwitterYouTube and Instagram

 

« back to overview